VERAXA Biotech AG (NASDAQ: VRXA) today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately. In this role, Erkel will lead the company's efforts to advance its proprietary BiTAC(R) platform technologies, which are designed to develop bispecific T cell engagers and other innovative antibody-based therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period.
Erkel brings more than two decades of experience in antibody therapeutics, antibody engineering and preclinical development. He previously served as Vice President of Research and Development at VERAXA and before that held leadership roles at MorphoSys AG, where he oversaw immuno-oncology programs focused on T-cell engagers. His background in managing multidisciplinary research programs is expected to support the expansion of VERAXA's oncology pipeline and advance BiTAC(R) candidates toward clinical development.
“We are delighted to appoint Christoph as Chief Scientific Officer. His extensive experience in antibody engineering and immuno-oncology will be invaluable as we continue to progress our BiTAC platform and pipeline,” said a company representative. The full press release can be accessed at https://nnw.fm/cR1RS.
VERAXA is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company's technologies are guided by rigorous quality-by-design principles and are rapidly advancing a pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The appointment of Erkel comes at a critical time for VERAXA as it seeks to advance its pipeline and capitalize on the growing interest in bispecific antibodies and T-cell engagers for cancer treatment. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. For more information, visit the company's newsroom at http://nnw.fm/VRXA.
